- JP-listed companies
- StemRIM Inc.
- Cash flow
StemRIM Inc. (4599) Cash flow
Market cap
¥19.3B
P/E ratio
StemRim develops regenerative induction pharmaceuticals that activate patients' own stem cells to repair damaged tissues using peptide-based drugs like Ledasemdide.
| 2018/07 | 2019/07 | 2020/07 | 2021/07 | 2022/07 | 2023/07 | 2024/07 | 2025/07 | |
| Depreciation & amortization | 1 | 2 | 8 | 44 | 49 | 48 | 44 | 49 |
| Cash from operations | -261 | -778 | 575 | -520 | -1,405 | 1,135 | -1,881 | -1,415 |
| Capital expenditures | - | -5 | -153 | -89 | -0 | - | -2 | -43 |
| Cash from investing | - | -7 | -154 | -93 | -0 | -0 | -5 | -42 |
| Repurchases of common stock | - | - | - | - | -0 | -0 | - | - |
| Cash from financing | 1,200 | 1,437 | 7,757 | 109 | 113 | 203 | 79 | 41 |
| Free cash flow | - | - | ||||||
| FCF margin (%) | - | - | - | - |